SCHEMBL6537088

SCHEMBL6537088

O=C(Nc1cccc2ccccc12)NS(=O)(=O)C(F)(F)F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.61
KMT2A Q03164 3/20 0.61
MEN1 O00255 2/20 0.61
NLRP3 Q96P20 1/20 0.57
MAPT P10636 1/20 0.55
GAA P10253 1/20 0.53
POLB P06746 3/20 0.52
CYP1A2 P05177 2/20 0.52
GSK3B P49841 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
RAB9A P51151 4/20 0.50
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
NPC1 O15118 2/20 0.50
EPHX1 P07099 2/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC8 Q9BY41 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6537093 0.80 NLRP3 (0.61) KDM4EKMT2AMEN1NLRP3MAPT
SCHEMBL19971762 0.79 KDM4E (0.58) KDM4EKMT2AMEN1NLRP3MAPT
SCHEMBL30393282 0.79 KDM4E (0.82) KDM4EKMT2AMEN1MAPTGAA
SCHEMBL1276481 0.79 KDM4E (0.82) KDM4EKMT2AMEN1MAPTGAA
SCHEMBL2127567 0.78 KEAP1 (0.61) KDM4EKMT2AMEN1MAPTGAA
SCHEMBL6465979 0.78 EPHX1 (0.62) KDM4EKMT2AMEN1NLRP3MAPT
SCHEMBL28884900 0.76 KDM4E (0.67) KDM4EKMT2AMEN1MAPTGAA
SCHEMBL22503161 0.76 MMP3 (0.56) KMT2AMEN1GAAPOLBSMN1; SMN2
SCHEMBL5551553 0.74 HDAC1 (0.70) KDM4EKMT2AMEN1MAPTGAA
SCHEMBL22503134 0.74 ACP1 (0.62) KMT2AMEN1MAPTSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0615859-B1 Thermosensitive recording material OJI PAPER CO (JP) 1998-06-03 EP claimed
US-5449657-A Sulfonyl (thio)ureas NEW OJI PAPER CO., LTD. (JP) 1995-09-12 US claimed
EP-0615859-A1 Thermosensitive recording material NEW OJI PAPER CO., LTD. (JP) 1994-09-21 EP claimed
US-11518739-B2 Sulfonamide carboxamide compounds INFLAZOME LIMITED (IE) 2022-12-06 US disclosed
US-20200216389-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2020-07-09 US disclosed
WO-2019034697-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 WO disclosed
US-6740465-B2 MULTILAYER; TRANSPARENT SUPPORT; HEAT SENSITIVE ELEMENT AND RELEASE AGENT SIPIX IMAGING, INC. 2004-05-25 US disclosed
EP-1289768-A2 IMAGING MEDIA CONTAINING HEAT DEVELOPABLE PHOTOSENSITIVE MICROCAPSULES Sipix Imaging, Inc. (US) 2003-03-12 EP disclosed
US-20020155372-A1 Imaging media containing heat developable photosensitive microcapsules SIPIX IMAGING, INC. 2002-10-24 US disclosed
WO-2001092024-A2 IMAGING MEDIA CONTAINING HEAT DEVELOPABLE PHOTOSENSITIVE MICROCAPSULES SIPIX IMAGING, INC. (US) 2001-12-06 WO disclosed
EP-0615859-B1 Thermosensitive recording material OJI PAPER CO (JP) 1998-06-03 EP disclosed
US-5449657-A Sulfonyl (thio)ureas NEW OJI PAPER CO., LTD. (JP) 1995-09-12 US disclosed
EP-0615859-A1 Thermosensitive recording material NEW OJI PAPER CO., LTD. (JP) 1994-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216389-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, PYCARD KDM4E 2695/4885KMT2A 3307/4885MEN1 3692/4885
US-11518739-B2 Sulfonamide carboxamide compounds NLRP3, PYCARD, NOD1 KDM4E 2596/4885KMT2A 3195/4885MEN1 3305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.